Sign up for free insights newsletter
TX

10X Genomics Inc

TXGUnited States

Need professional-grade analysis? Visit stockanalysis.com

$18.39
+5.99%
End of day
Market Cap

$2.45B

P/E Ratio

N/A

Employees

N/A

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino1.272.901.822.04
Calmar2.174.662.463.12
Sharpe0.801.601.081.18
Omega1.191.291.221.24
Martin4.429.935.706.79
Ulcer12.3411.8313.5312.66

10X Genomics Inc (TXG) Price Performance

10X Genomics Inc (TXG) trades on United States in USD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at $18.39, up 5.99% from the previous close.

Over the past year, TXG has traded between a low of $7.14 and a high of $23.19. The stock has gained 88.6% over this period. It is currently 20.7% below its 52-week high.

10X Genomics Inc has a market capitalization of $2.45B.

About 10X Genomics Inc

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$642.82M
EBITDA
$-64,086,000
Profit Margin
-6.77%
EPS (TTM)
-0.35
Book Value
6.24

Technical Indicators

52 Week High
$23.56
52 Week Low
$6.78
50 Day MA
$19.96
200 Day MA
$15.07
Beta
2.21

Valuation

Trailing P/E
N/A
Forward P/E
117.19
Price/Sales
3.80
Price/Book
3.07
Enterprise Value
$2.01B